Expression of ifn-γ before and after treatment of oral lichen planus with 0.1% fluocinolone acetonide in orabase

Journal of Oral Pathology and Medicine

Volumn 38, Issue 9, 2009, Pages 689-694

  Youngnak Piboonratanakit, Pornpan ^a   Dhanuthai, Kittipong ^a   Thongprasom, Kobkan ^a   Luckprom, Pimporn ^a   Sarideechaigul, Wilairat ^b   Luangjarmekorn, Lakana ^a   Azuma, Miyuki ^c  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b NARESUAN UNIVERSITY   (Thailand)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Fluocinolone acetonide; Interferon ; Oral lichenplanus

Indexed keywords

FLUOCINOLONE ACETONIDE; GAMMA INTERFERON;

ADULT; ARTICLE; ATROPHY; CELL COUNT; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; LICHEN PLANUS; MALE; MONONUCLEAR CELL; MOUTH ULCER; ORAL BIOPSY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION;

ADMINISTRATION, TOPICAL; ADULT; CARBOXYMETHYLCELLULOSE; FEMALE; FLUOCINOLONE ACETONIDE; GLUCOCORTICOIDS; HUMANS; IMMUNOMODULATION; INTERFERON-GAMMA; KERATINOCYTES; LEUKOCYTES, MONONUCLEAR; LICHEN PLANUS, ORAL; MALE; MIDDLE AGED; OINTMENTS;

EID: 70350335626     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2009.00805.x     Document Type: Article

References (38)

1. Ismail SB, Kumar SK, Zain RB. Oral lichen planus and lichenoid reactions: etiopathogenesis, diagnosis, management and malignant transformation. J Oral Sci 2007; 49: 89-106.
2. Sugerman PB, Savage NW, Walsh LJ, et al. The pathoge esis of oral lichen planus. Crit Rev Oral Biol Med 2002; 13: 350-365
3. Thornhill MH. Immune mechanisms in oral lichen planus. Acta Odontol Scand 2001; 59: 174-177
4. Fayyazi A, Schweyer S, Soruri A, et al. T lymphocytes and altered keratinocytes express interferon-gamma and nterleukin 6 in lichen planus. Arch Dermatol Res 1999; 291:485-490
5. Schoenborn JR, Wilson CB. Regulation of interferongamma during innate and adaptive immune responses. Adv Immunol 2007; 96: 41-101.
6. Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferongamma: an overview of signals, mechanisms and functions. J Leukoc Biol 2004; 75: 163-189
7. Szegedi A, Aleksza M, Gonda A, et al. Elevated rate of T helper1 (T(H)1) lymphocytes and serum IFN-gamma levels in psoriatic patients. Immunol Lett 2003; 86: 277-280
8. Arican O, Aral M, Sasmaz S, Ciragil P. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. ediators Inflamm 2005; 2005: 273-279
9. Kawashima M, Miossec P. mRNA quantification of T-bet, GATA-3, IFN-gamma, and IL-4 shows a defective Th1 immune response in the peripheral blood from rheumatoid arthritis patients: link with disease activity. J Clin Immunol 2005; 25: 209-214
10. Muratov V, Lundahl J, Ulfgren AK, et al. Down-regulation of interferon-gamma parallels clinical response to selective leukocyte apheresis in patients with inflammatory bowel disease: a 12-month follow-up study. Int J Colorectal Dis 2006; 21: 493-504.
11. Halminen M, Simell O, Knip M, Ilonen J. Cytokine expression in unstimulated PBMC of children with type 1 diabetes and subjects positive for diabetes-associated autoantibodies. Scand J Immunol 2001; 53: 510-513
12. Simark Mattsson C, Jontell M, Bergenholtz G, Heyden M, Dahlgren UI. Distribution of interferon-gamma mRNApositive cells in oral lichen planus lesions. J Oral Pathol ed 1998; 27: 483-488
13. Yamamoto T, Osaki T. Characteristic cytokines generated by keratinocytes and mononuclear infiltrates in oral lichen planus. J Invest Dermatol 1995; 104: 784-788
14. Khan A, Farah CS, Savage NW, Walsh LJ, Harbrow DJ, Sugerman PB. Th1 cytokines in oral lichen planus. J Oral Pathol Med 2003; 32: 77-83.
15. Tao XA, Li CY, Rhodus NL, Xia J, Yang XP, Cheng B. Simultaneous detection of IFN-gamma and IL-4 in lesional tissues and whole unstimulated saliva from patients with oral lichen planus. J Oral Pathol Med 2008; 37: 83-87
16. Bai J, Lin M, Zeng X, et al. Association of polymorphisms in the human IFN-gamma and IL-4 gene with oral lichen planus: a study in an ethnic Chinese cohort. J Interferon ytokine Res 2008; 28: 351-358
17. Carrozzo M, Uboldi de Capei M, Dametto E, et al. Tumor necrosis factor-alpha and interferon-gamma polymorphisms contribute to susceptibility to oral lichen lanus. J Invest Dermatol 2004; 122: 87-94.
18. Al-Hashimi I, Schifter M, Lockhart PB, et al. Oral lichen planus and oral lichenoid lesions: diagnostic and therapeutic considerations. Oral Surg Oral Med Oral Pathol ral Radiol Endod 2007; 103 Suppl: S25 e1-12.
19. Thongprasom K, Dhanuthai K. Steriods in the treatment of lichen planus: a review. J Oral Sci 2008; 50: 377-385
20. Thongprasom K, Luangjarmekorn L, Sererat T, Taweesap W. Relative efficacy of fluocinolone acetonide compared with triamcinolone acetonide in treatment of oral lichen lanus. J Oral Pathol Med 1992; 21: 456-458
21. Thongprasom K, Luengvisut P, Wongwatanakij A, Boonjatturus C. Clinical evaluation in treatment of oral lichen planus with topical fluocinolone acetonide: a 2-year follow-up. J Oral Pathol Med 2003; 32: 315-322
22. Thongprasom K, Dhanuthai K, Sarideechaigul W, Chaiyarit P, Chaimusig M. Expression of TNF-alpha in oral lichen planus treated with fluocinolone acetonide 0.1%. J Oral Pathol Med 2006; 35: 161-166
23. Rhodus NL, Cheng B, Bowles W, Myers S, Miller L, Ondrey F. Proinflammatory cytokine levels in saliva before and after treatment of (erosive) oral lichen planus with dexamethasone. Oral Dis 2006; 12: 112-116
24. Albanesi C, Cavani A, Girolomoni G. Interferon-gammastimulated human keratinocytes express the genes necessary for the production of peptide-loaded MHC class II olecules. J Invest Dermatol 1998; 110: 138-142
25. Li J, Farthing PM, Thornhill MH. Cytokine regulation of major histocompatibility complex antigen expression by human oral and skin keratinocytes. Arch Oral Biol 1996; 41: 533-538 (Pubitemid 27081757)
26. Bennion SD, Middleton MH, David-Bajar KM, Brice S, Norris DA. In three types of interface dermatitis, different patterns of expression of intercellular adhesion molecule-1 ICAM-1) indicate different triggers of disease. J Invest Dermatol 1995; 105: 71S-9S.
27. Youngnak-Piboonratanakit P, Tsushima F, Otsuki N, et al. The expression of B7-H1 on keratinocytes in chronic inflammatory mucocutaneous disease and its regulatory ole. Immunol Lett 2004; 94: 215-222
28. Boenisch T. Handbook on immunohistochemical staining methods, 3rd edn. Carpinteria, CA: DAKO Corporation, 2001.
29. Ramos-Vara JA. Technical aspects of immunohistochemistry. Vet Pathol 2005; 42: 405-426
30. Erdem MT, Gulec AI, Kiziltunc A, Yildirim A, Atasoy M. Increased serum levels of tumor necrosis factor alpha in lichen lanus. Dermatology 2003; 207: 367-370
31. Zhang Y, Lin M, Zhang S, et al. NF-kappaB-dependent cytokines in saliva and serum from patients with oral lichen planus: a study in an ethnic Chinese population. Cytokine 2008; 41: 144-149
32. Sklavounou-Andrikopoulou A, Chrysomali E, Iakovou M, Garinis GA, Karameris A. Elevated serum levels of the apoptosis related molecules TNF-alpha, Fas / Apo-1 and cl-2 in oral lichen planus. J Oral Pathol Med 2004; 33: 386-390
33. Jacob SE, Nassiri M, Kerdel FA, Vincek V. Simultaneous measurement of multiple Th1 and Th2 serum cytokines in psoriasis and correlation with disease severity. Mediators nflamm 2003; 12: 309-313
34. Bonifati C, Ameglio F. Cytokines in psoriasis. Int J Dermatol 1999; 38: 241-251
35. Rhodus NL, Cheng B, Myers S, Bowles W, Ho V, Ondrey F. A comparison of the pro-inflammatory, NF- appaBdependent cytokines: TNF-alpha, IL-1-alpha, IL-6, and IL-8 in different oral fluids from oral lichen planus patients. Clin Immunol 2005; 114: 278-283
36. Pezelj-Ribaric S, Prso IB, Abram M, Glazar I, Brumini G, Simunovic-Soskic M. Salivary levels of tumor necrosis factor-alpha in oral lichen planus. Mediators Inflamm 2004; 13: 131-133
37. Rhodus NL, Cheng B, Ondrey F. Th1 / Th2 cytokine ratio in tissue transudates from patients with oral lichen planus. Mediators Inflamm 2007; 2007: 19854.
38. Gonzalez-Moles MA, Scully C. Vesiculo-erosive oral mucosal disease - management with topical corticosteroids: (1) fundamental principles and specific agents available. J Dent Res 2005; 84: 294-301. (Pubitemid 43822008)